Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine-based Chemoradiotherapy With Anakinra for Rectal Cancer
NCT04942626Phase 1Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anakinra in rectal cancer, sponsored by Goethe University Frankfurt. Primary endpoints: Analysis of safety at 16 weeks and Maximum Tolerated Dose at 16 weeks. Started Aug 2021; status: completed.
02
Drugs
anakinra
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04942626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942626.